
NSF/IPEC/ANSI 363 - 2019

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients
NSF International, an independent, not-for-profit, nongovernmental organization, is dedicated to being the leading global provider of public health and safety-based risk management solutions while serving the interests of all stakeholders.

This Standard is subject to revision. Contact NSF to confirm this revision is current.

Users of this Standard may request clarifications and interpretations, or propose revisions by contacting:

Chair, Joint Committee on Pharmaceutical Excipients
c/o NSF International
789 North Dixboro Road, PO Box 130140
Ann Arbor, Michigan 48113-0140 USA
Phone: (734) 769-8010 Fax: (734) 769-0109
Email: info@nsf.org
Web: <www.nsf.org>
NSF/IPEC/ANSI 363 – 2019

NSF International Standard /
International Pharmaceutical Excipients Council /
American National Standard
for Pharmaceutical Excipients –

Good Manufacturing Practices (GMP)
for Pharmaceutical Excipients

Standard Developer
NSF International

Designated as an ANSI Standard
September 20, 2019
American National Standards Institute
NSF International (NSF), in performing its functions in accordance with its objectives, does not assume or undertake to discharge any responsibility of the manufacturer or any other party. The opinions and findings of NSF represent its professional judgment. NSF shall not be responsible to anyone for the use of or reliance upon this Standard by anyone. NSF shall not incur any obligation or liability for damages, including consequential damages, arising out of or in connection with the use, interpretation of, or reliance upon this Standard. It is the responsibility of the user of this standard to judge the suitability of the ANSI for the user's purpose.

NSF Standards provide basic criteria to promote sanitation and protection of public health and the environment. Provisions for mechanical and electrical safety have not been included in this Standard because governmental agencies or other national standards-setting organizations provide safety requirements.

Participation in NSF Standards development activities by regulatory agency representatives (federal, state, or local) shall not constitute their agency's endorsement of NSF or any of its Standards.

Preference is given to the use of performance criteria measurable by examination or testing in NSF Standards development when such performance criteria may reasonably be used in lieu of design, materials, or construction criteria.

The illustrations, if provided, are intended to assist in understanding their adjacent standard requirements. However, the illustrations may not include all requirements for a specific product or unit, nor do they show the only method of fabricating such arrangements. Such partial drawings shall not be used to justify improper or incomplete design and construction.

At the time of this publication, examples of programs and processes were provided for general guidance. This information is given for the convenience of users of this standard and does not constitute an endorsement by NSF International. Equivalent programs and processes may be used.

Unless otherwise referenced, the annexes are not considered an integral part of NSF Standards. The annexes are provided as general guidelines to the manufacturer, regulatory agency, user, or certifying organization.

---

1 The information contained in this Disclaimer is not part of this American National Standard (ANS) and has not been processed in accordance with ANSI's requirements for an ANS. Therefore, this Disclaimer may contain material that has not been subjected to public review or a consensus process. In addition, it does not contain requirements necessary for conformance to the Standard.
This page is intentionally left blank.
Contents
1 General ................................................................................................................................................. 1
1.1 Scope ............................................................................................................................................... 1
1.2 Purpose ........................................................................................................................................... 1
2 Reference documents .......................................................................................................................... 1
2.1 Normative references ...................................................................................................................... 1
2.2 Informational references ................................................................................................................ 2
3 Definitions ........................................................................................................................................... 3
4 Context of the organization ..................................................................................................................... 7
4.1 Understanding the organization and its context ............................................................................. 7
4.2 Understanding the needs and expectations of interested parties ...................................................... 8
4.3 Determining the scope of the QMS .................................................................................................. 8
4.4 QMS and its processes .................................................................................................................... 8
5 Leadership ........................................................................................................................................... 9
5.1 Management commitment ............................................................................................................... 9
5.2 Quality policy .................................................................................................................................. 9
5.3 Organizational roles, responsibilities and authorities ..................................................................... 10
6 Planning .............................................................................................................................................. 10
6.1 Actions to address risks and opportunities .................................................................................... 10
6.2 Quality objectives and planning to achieve them ......................................................................... 11
6.3 Planning of changes ....................................................................................................................... 11
7 Support .............................................................................................................................................. 11
7.1 Resources ....................................................................................................................................... 11
7.2 Competence .................................................................................................................................... 16
7.3 Awareness ....................................................................................................................................... 16
7.4 Communication ............................................................................................................................... 17
7.5 Documented information ............................................................................................................... 17
8 Operation .......................................................................................................................................... 19
8.1 Operational planning and control .................................................................................................. 19
8.2 Requirements for products and services ....................................................................................... 19
8.3 Design and development (out of scope) ....................................................................................... 20
8.4 Control of externally provided processes, products, and services ................................................ 20
8.5 Production and service provision .................................................................................................. 20
8.6 Monitoring and measurement of product ....................................................................................... 23
8.7 Control of nonconforming materials ............................................................................................. 24
9 Performance evaluation ....................................................................................................................... 26
9.1 Monitoring, measurement, and analysis ....................................................................................... 26
9.2 Internal audit .................................................................................................................................... 29
9.3 Management review ....................................................................................................................... 29
10 Improvement .................................................................................................................................... 30
10.1 General ......................................................................................................................................... 30
10.2 Nonconformity and corrective action ............................................................................................ 30
10.3 Continual improvement ................................................................................................................. 30
This page is intentionally left blank.
Foreword

NSF/IPEC/ANSI 363 defines minimum cGMP standards for the manufacture and distribution of pharmaceutical excipients. Certification to this Standard serves as a communication tool between manufacturers of excipients and finished product manufacturers, pharmaceutical regulators, pharmacy organizations, and consumers.

NSF/IPEC/ANSI 363 was developed with participation from the pharmaceutical excipients manufacturers, public health regulators, and distributors of pharmaceutical excipients.

This edition of the Standard contains the following revisions:

Issue 11
This revision adds more options for signatures on the Certificate of Analysis is Section 8.2.4.5.

Issue 12
This revision updates the language in Section 6.3.2.1.

Issue 13
This revision removes “waste segregation and disposal” from the form in Section 6.4.

Issue 14
This revision updates the entire standard to be better mapped to the new ISO 9001 format.

This Standard was developed by the NSF Joint Committee on Pharmaceutical Excipients using the consensus process described by the American National Standards Institute.

This Standard and the accompanying text are intended for voluntary use by certifying organizations, regulatory agencies, and/or manufacturers as a basis of providing assurances that adequate health protection exists for covered products.

Suggestions for improvement of this Standard are welcome. This Standard is maintained on a continuous maintenance schedule and can be opened for comment at any time. Comments should be sent to: Chair, Joint Committee on Pharmaceutical Excipients at standards@nsf.org, or c/o NSF International, Standards Department, PO Box 130140, Ann Arbor, Michigan 48113-0140, USA.

---

2 The information contained in this Foreword is not part of this American National Standard (ANS) and has not been processed in accordance with ANSI’s requirements for an ANS. Therefore, this Foreword may contain material that has not been subjected to public review or a consensus process. In addition, it does not contain requirements necessary for conformance to the Standard.
1 General

1.1 Scope

This Standard is intended to define good manufacturing practices (GMP) for excipient manufacture and distribution for use in drug products. It sets minimum requirements for GMP applicable to all commercially available excipients.

NOTE 1 — The requirements of this Standard may not be sufficient for all applications of excipients. It is the user's responsibility to determine whether or not this Standard meets the requirements for their intended use.

NOTE 2 — Auditing excipient manufacturers ensures conformance to this Standard. This Standard is also intended to be used by duly accredited or otherwise suitably qualified third-party audit and certification providers.

NOTE 3 — Each user of a third-party auditing service should make its own determination as to the qualifications of the third party and the applicability of the report and/or certificate issued in satisfying its requirements, including those pertaining to its intended use of the excipient.

1.2 Purpose

Excipients impact the appearance, stability, and delivery of drug products, and are essential to the safety, quality, and efficacy of these products. It is not possible to assure the consistent quality of excipients by testing alone. Adherence to excipient GMP provides assurance that excipients are suitable for use in drug products. Excipient GMP require a proper quality management system (QMS), test methods, and facilities and controls.

2 Reference documents

2.1 Normative references

The following documents contain requirements that, by reference in this text, constitute requirements of this Standard. At the time of publication, the indicated editions were valid. All of the documents are subject to revision and parties shall investigate the possibility of applying the recent editions of the documents indicated below. The most recent published edition of the document shall be used for undated references.


3 GMP applies to distribution per the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 USC. 501(a) (2) (B).

4 World Health Organization (WHO). 20 Avenue Appia, 1211 Geneva 27, Switzerland. <www.who.int>